Medical Pharmacology: Cancer Chemotherapy Drugs: Anti-Metabolites (Anti-Microtubule) Practice Questions

Medical Pharmacology: Cancer Chemotherapy Anti-Metabolite (Anti-Microtubule) Practice Questions

1 / 10

Which one(s) of the following statements is/are correct?
1. Taxanes are classified as microtubule stabilizing agents.
2. Both docetaxel and paclitaxel exhibit resistance to the P-glycoprotein reflux pump the activity of which results in resistant to the anti-cancer activity of these agents.
3. Both
4. Neither
Initial regulatory approval in the United States for paclitaxel was for ovarian cancer patients who fail first-line or follow-on chemotherapy.
1. True
2. False
Contemporary indication(s) for paclitaxel:
1. Advanced breast cancer
2. Component in combination chemotherapy in lymph node-positive breast cancer (adjuvant treatment)
3. In advanced ovarian cancer given in combination with a platinum agent.
4. Second-line management of AIDS-related Kaposi sarcoma
5. First-line treatment in non-small cell lung cancer (NSCLC)
6. A & B
7. A, B & C
8. All answers (A - E)
Common toxicities associated with paclitaxel administration:
1. Myelosuppression
2. Alopecia
3. Peripheral neuropathy
4. A & B
5. B & C
6. A, B & C
Some Docetaxel use/uses:
1. For metastatic breast cancer following progression or relapse after anthracycline-based chemotherapy.
2. Adjuvant treatment status for stage II breast cancer when given in combination with Adriamycin and cyclophosphamide (TAC).
3. In metastatic castration-resistant prostate cancer when given along with prednisone
4. First-line treatment of gastric adenocarcinoma
5. Inoperable and locally advanced squamous cell head and neck cancer given in combination therapy with 5-fluorouracil (5-FU) and cisplatin
6. A & C
7. C, D & F
8. All answer options (A-E)
One anticancer mechanism for paclitaxel: ß-tubular binding causing mitotic arrest at G2/M transition point, resulting in induced cell death.
1. True
2. False
Peripheral neuropathy represents a common and dose-limiting toxicity of anti-microtubule drugs, likely due to direct action on microtubules.
1. True
2. False
Paclitaxel elimination:
1. Renal
2. In the feces
3. Both
4. Neither
The primary drug disposition mechanism is metabolism by the cytochrome P450 microsomal enzyme system, especially by the CYP2C8 and CYP3A4 isoforms.
1. True
2. False
Nanoparticlesalbumin bound (NAB) paclitaxel:
1. This combination has been approved for patients with metastatic breast cancer
2. This combination has been approved for patients given in combination of carboplatin as first-line treatment in both locally advanced or metastatic non-small cell lung cancer (NSCLC)
3. Nanoparticle albumin-bound paclitaxel administration appears to result in improved clinical response compared to solvent-based paclitaxel.
4. A & B
5. A, B & C